🚀 The Mega-Merger That Wasn’t Early August saw the Financial Times report that AstraZeneca and Bristol Myers Squibb (BMS) were in “early-stage talks” about a potential $400 billion merger. The market reaction was immediate: AstraZeneca shares dropped nearly 9% in London, while BMS shares rose in the US. However, within days, a senior source told…
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
